Madrigal Pharmaceuticals, Inc. (MDGL:NASDAQ) closed at $399.63 on November 6, 2026, down 0.12% on the day. The stock trades 35.0% below its 52-week high of $615.00 and 13.0% above its 52-week low of $353.54. Over the past year, it lost 18.3%. Madrigal Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 6, 2025, MDGL closed higher on 123 days (49%). Its best day was March 26, 2026 (+12.30%) and its worst was February 19, 2026 (-11.11%). The stock moved 10% or more in a single session 2 times.
Synta Pharmaceuticals Corp. focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its clinical stage drug candidate in oncology is ganetespib, an Hsp90 inhibitor, which is in Phase II clinical trials to evaluate the combination of ganetespib and paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma, including malignant peripheral nerve sheath tumors. The company's drug candidate in its Hsp90-inhibitor Drug Conjugate program is STA-12-8666, which is in preclinical trials for chemotherapy irinotecan. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.
Find more stocks like MDGL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.